Flow, Fatty Acid Biosynthesis, and Hematopoiesis
流动、脂肪酸生物合成和造血
基本信息
- 批准号:10868960
- 负责人:
- 金额:$ 15万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-08-01 至 2024-07-31
- 项目状态:已结题
- 来源:
- 关键词:AccelerationAnemiaAortaAttenuatedBindingBinding ProteinsBloodBlood VesselsBlood flowCell Fate ControlCell NucleusCellsDataDevelopmentDinoprostoneDiseaseDocosahexaenoic AcidsEicosanoidsEmbryonic DevelopmentEndothelial CellsEndotheliumEngineeringEngraftmentExposure toFatty AcidsFrictionFutureGenerationsGenesGenetic TranscriptionGonadal structureHematologic NeoplasmsHematological DiseaseHematologyHematopoiesisHematopoieticHematopoietic Stem Cell TransplantationHematopoietic stem cellsHumanImmuneImmune System DiseasesImpairmentIn VitroKnowledgeLiquid substanceLiteratureMesonephric structureMetabolic DiseasesMissionMolecularMolecular ChaperonesMorbidity - disease rateMusMutationNuclearOmega-3 Fatty AcidsOutcomeOutputPathway interactionsPatientsPhasePhysical condensationPilot ProjectsPolyunsaturated Fatty AcidsPopulationProceduresProliferatingProtein InhibitionPublic HealthPublicationsRegulatory ElementRegulatory PathwayResearchSCAP proteinScientistSignal TransductionSpecific qualifier valueSterolsSupplementationSystemTP53 geneTestingTherapeuticTranscription CoactivatorTranscriptional RegulationUmbilical Cord BloodUnited States National Institutes of HealthWorkZebrafishcell fate specificationcellular engineeringchemotherapycofactordisabilitydonor stem cellfatty acid biosynthesisheart functionhematopoietic cell transplantationhematopoietic stem cell emergencehematopoietic stem cell fatehemogenic endotheliumimmune functionimprovedin vivoinduced pluripotent stem cellirradiationlipid biosynthesislipid metabolismmechanical propertiesmortalitynoveloverexpressionprogramsprotein expressionreconstitutionresponseshear stressstem cellstranscription factor
项目摘要
(PLEASE KEEP IN WORD, DO NOT PDF)
Hematopoietic stem cells (HSCs), which give rise to the full spectrum of hematological cells in the blood, hold tremendous promise as future treatments for hematological and immunological diseases. For example, HSC transplantation can reconstitute the blood system following irradiation or chemotherapy, thus restoring immune function and improving anemia in patients undergoing such treatments. Furthermore, therapies that could modulate the regulatory pathways controlling cell fate could help treat metabolic disorders caused by unrestricted proliferation of HSCs and hematopoietic progenitor cells. Unfortunately, to date scientists have limited capability to expand multipotent HSCs ex vivo from cord blood. Even with sufficient HSCs, if they are not properly engrafted, transplanted HSCs can cause serious morbidity or mortality. Finally, compatibility challenges between HSC donors and recipients create additional difficulty. These challenges impede the broader application of hematopoietic cell transplantation procedures.
One attractive alternative is to generate HSCs in vitro using cell engineering. The overall objective of this application is to identify the key molecular mechanisms controlling HSC emergence during embryonic development. This knowledge can be harnessed to guide de novo generation of HSPCs in vitro. Preliminary results have led to the rationale that fatty acid biosynthesis–activated by shear stress imposed on the vascular wall–dictates hematopoietic development. These pilot studies have revealed a novel flow-regulated lipid metabolism program orchestrating hematopoiesis. Based on rigorous preliminary research and previous publications by this team and others, the central hypothesis is that endogenous fatty acid biosynthesis facilitates HSPC fate commitment from human-induced pluripotent stem cells. The central hypothesis will be investigated through two specific aims that will examine whether the natural fatty acid synthesis program controls HSPC fate specification from human-induced pluripotent stem cells. Upon completion of this work, the results will define a critical flow-regulated lipid metabolism pathway that instructs definitive hematopoiesis.
(请保存文字,不要使用pdf格式)
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Longhou Fang其他文献
Longhou Fang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Longhou Fang', 18)}}的其他基金
AIBP Mediates a Novel Interplay between Cholesterol Metabolism and Lymphangiogenesis
AIBP 介导胆固醇代谢和淋巴管生成之间的新相互作用
- 批准号:
9247254 - 财政年份:2016
- 资助金额:
$ 15万 - 项目类别:
AIBP-Mediated Cholesterol Efflux and Angiogenesis
AIBP 介导的胆固醇流出和血管生成
- 批准号:
8929458 - 财政年份:2014
- 资助金额:
$ 15万 - 项目类别:
AIBP-Mediated Cholesterol Efflux and Angiogenesis
AIBP 介导的胆固醇流出和血管生成
- 批准号:
9178668 - 财政年份:2014
- 资助金额:
$ 15万 - 项目类别:
AIBP-mediated Cholesterol Efflux and Angiogenesis
AIBP 介导的胆固醇流出和血管生成
- 批准号:
8353288 - 财政年份:2012
- 资助金额:
$ 15万 - 项目类别:
AIBP-Mediated Cholesterol Efflux and Angiogenesis
AIBP 介导的胆固醇流出和血管生成
- 批准号:
8528713 - 财政年份:2012
- 资助金额:
$ 15万 - 项目类别:
相似国自然基金
基于构建骨骼类器官模型探究Fanconi anemia信号通路调控电刺激诱导神经化成骨过程的机制研究
- 批准号:82302715
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
FANCM蛋白在传统Fanconi anemia通路以外对保护基因组稳定性的功能
- 批准号:
- 批准年份:2021
- 资助金额:10.0 万元
- 项目类别:省市级项目
范可尼贫血(Fanconi Anemia)基因FANCM在复制后修复中的作用及FA癌症抑制通路的机制研究
- 批准号:31200592
- 批准年份:2012
- 资助金额:23.0 万元
- 项目类别:青年科学基金项目
相似海外基金
Investigation of crosstalk between Fanconi Anemia pathway and ATM for novel therapeutic strategies of chemoresistant ALT-positive high-risk neuroblastoma
范可尼贫血通路与 ATM 之间的串扰研究,用于化疗耐药 ALT 阳性高危神经母细胞瘤的新治疗策略
- 批准号:
24K10442 - 财政年份:2024
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Immune escape mechanisms in BCOR/BCORL1 mutant hematopoietic stem cells from patients with aplastic anemia
再生障碍性贫血患者 BCOR/BCORL1 突变型造血干细胞的免疫逃逸机制
- 批准号:
23K15297 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Fanconi anemia経路に着目したiPS細胞における高レベル複製ストレスの原因解明
阐明 iPS 细胞中高水平复制应激的原因,重点关注范可尼贫血途径
- 批准号:
23K14452 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Analysis of the mechanism of hemolytic anemia in canine babesiosis and development of novel therapeutic measures
犬巴贝斯虫病溶血性贫血机制分析及新治疗措施开发
- 批准号:
23KJ0074 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Brain blood flow, oxygenation, and cognition in adult onset iron deficiency anemia
成人缺铁性贫血的脑血流量、氧合和认知
- 批准号:
10735765 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Chromatin State Alterations in Fanconi Anemia Hematologic Disease and Bone Marrow Failure
范可尼贫血血液疾病和骨髓衰竭中的染色质状态改变
- 批准号:
10735366 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Liver-Gut Axis in Neonatal Anemia and Its Role in RBC Transfusion Associated Gut Injury
新生儿贫血中的肝肠轴及其在红细胞输注相关肠道损伤中的作用
- 批准号:
10583807 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Small Molecule Therapeutics for Sickle Cell Anemia
镰状细胞性贫血的小分子疗法
- 批准号:
10601679 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Accuracy and Feasibility of Non-Invasive Anemia Screening Assistant (ASIST) Device in Resource-Limited Settings
资源有限环境中非侵入性贫血筛查辅助 (ASIST) 设备的准确性和可行性
- 批准号:
10575222 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别:
Mobile phone-based screening for anemia in young children in western Kenya
基于手机的肯尼亚西部幼儿贫血筛查
- 批准号:
10752968 - 财政年份:2023
- 资助金额:
$ 15万 - 项目类别: